Of inhalable aztreonam lysinate Formulation for the treatment and Prevention of bacterial Lung infections

摘要

A method and a composition for the treatment of Lung bacterial infections caused by Gram negative bacterium for Treatment of infections caused by Escherichia coli, Klebsiella pneumoniae, K.This haaemophilus influenzae, Pseudomonas aeruginosa, Proteus mirabilis, Enterobacter species, Serratia marcescens, as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans and multi drug resistant Pseudomonas aeruginosa.Using a Concentrated of aztreonam lysinate formulation released as an aerosol or as a dry powder inhalation. A process for the manufacture of aztreonam lysinate.Claim 1: a method for the treatment of Lung infections caused by gram-negative bacteria, Said method comprising the following steps: a) preparing an inhalable aztreonam lysinate formulation of concentrated around 1 250mg of aztreonam lysinate The lysinate of aztreonam dry powder inhalationOr about 1 to about 250 mg of aztreonam lysinate or a pharmaceutically acceptable Salt, dissolved in about 1 to about 5 ml of solution in a spray that contains about 0.1 to about 0.9% chloride or equivalent; and (b) that the release or dry powder aerosol solution of aztreonam lysinate endobronchial Space of the Airways of the Lungs of a patient in need through a Mist Spray with average diameter Masi Between approximately 1% and about 5 microns.Claim 1: a pharmaceutically acceptable composition comprising approximately 1 inhalable aztreonam lysinate of 250 mg per doseSaid composition is suitable for the treatment of Lung bacterial infections caused by gram-negative bacteria where the aztreonam lysinate comprised of equimolar amounts of aztreonam lysinate and prepared as a dry powder inhalation. 34: a Vindication of aztreonam lysinate Purified Alpha for the treatment of Lung infections caused by Gram negative bacteria.